A detailed history of Berkshire Asset Management LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Berkshire Asset Management LLC holds 4,403 shares of VRTX stock, worth $1.8 Million. This represents 0.1% of its overall portfolio holdings.

Number of Shares
4,403
Previous 4,403 -0.0%
Holding current value
$1.8 Million
Previous $2.06 Million 0.78%
% of portfolio
0.1%
Previous 0.1%

Shares

22 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$392.81 - $485.53 $1.73 Million - $2.14 Million
4,403 New
4,403 $2.06 Million
Q1 2024

May 14, 2024

SELL
$407.69 - $446.08 $31,392 - $34,348
-77 Reduced 1.58%
4,789 $2 Million
Q4 2023

Feb 09, 2024

SELL
$343.0 - $410.68 $7,889 - $9,445
-23 Reduced 0.47%
4,866 $1.98 Million
Q3 2023

Nov 14, 2023

SELL
$338.18 - $362.46 $16,570 - $17,760
-49 Reduced 0.99%
4,889 $1.7 Million
Q2 2023

Aug 14, 2023

BUY
$314.42 - $351.91 $39,302 - $43,988
125 Added 2.6%
4,938 $1.74 Million
Q1 2023

Jun 06, 2023

BUY
$283.23 - $323.1 $1.36 Million - $1.56 Million
4,813 New
4,813 $1.52 Million
Q3 2022

Nov 14, 2022

SELL
$273.83 - $305.53 $318,190 - $355,025
-1,162 Reduced 18.95%
4,969 $1.44 Million
Q2 2022

Aug 12, 2022

SELL
$234.96 - $292.55 $262,920 - $327,363
-1,119 Reduced 15.43%
6,131 $1.73 Million
Q1 2022

May 16, 2022

SELL
$221.42 - $260.97 $604,919 - $712,970
-2,732 Reduced 27.37%
7,250 $1.89 Million
Q4 2021

Feb 14, 2022

SELL
$177.01 - $223.45 $36,287 - $45,807
-205 Reduced 2.01%
9,982 $2.19 Million
Q3 2021

Nov 15, 2021

SELL
$181.39 - $202.99 $11,790 - $13,194
-65 Reduced 0.63%
10,187 $1.85 Million
Q2 2021

Aug 16, 2021

SELL
$187.49 - $221.1 $222,363 - $262,224
-1,186 Reduced 10.37%
10,252 $2.07 Million
Q1 2021

May 17, 2021

BUY
$207.02 - $241.31 $854,785 - $996,368
4,129 Added 56.49%
11,438 $2.46 Million
Q4 2020

Feb 16, 2021

BUY
$207.01 - $276.09 $939,411 - $1.25 Million
4,538 Added 163.77%
7,309 $1.73 Million
Q3 2020

Nov 16, 2020

BUY
$255.65 - $303.1 $92,034 - $109,116
360 Added 14.93%
2,771 $754,000
Q2 2020

Aug 12, 2020

SELL
$225.48 - $295.8 $600,904 - $788,307
-2,665 Reduced 52.5%
2,411 $700,000
Q1 2020

May 13, 2020

BUY
$199.77 - $247.81 $661,438 - $820,498
3,311 Added 187.59%
5,076 $1.21 Million
Q4 2019

Feb 12, 2020

SELL
$166.71 - $223.91 $8,168 - $10,971
-49 Reduced 2.7%
1,765 $386,000
Q2 2019

Jul 29, 2019

BUY
$164.61 - $190.37 $57,778 - $66,819
351 Added 23.99%
1,814 $333,000
Q4 2018

Jan 24, 2019

SELL
$151.91 - $192.21 $60,764 - $76,884
-400 Reduced 21.47%
1,463 $242,000
Q4 2017

Jan 17, 2018

SELL
$137.28 - $155.55 $3,569 - $4,044
-26 Reduced 1.38%
1,863 $279,000
Q3 2017

Oct 30, 2017

BUY
$148.13 - $162.24 $279,817 - $306,471
1,889
1,889 $287,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $105B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Berkshire Asset Management LLC Portfolio

Follow Berkshire Asset Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Berkshire Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Berkshire Asset Management LLC with notifications on news.